Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil

Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil

INTRODUCTIONWe conducted a cost-utility analysis of available interferon-free treatments for patients with early-stage genotype 1 chronic hepatitis C based on a Brazilian public health system perspective. METHODSA Markov model was derived using a cohort of stage F0-F2 patients treated as recommended...

Full description

Saved in:
Bibliographic Details
Published in:Revista da Sociedade Brasileira de Medicina Tropical Vol. 53; p. e20190594
Main Authors: Ferreira, Vinicius Lins, Leonart, Leticia Paula, Pedroso, Maria Lucia Alves, Pontarolo, Roberto
Format: Journal Article
Language:English
Published: Sociedade Brasileira de Medicina Tropical - SBMT 01-01-2020
Sociedade Brasileira de Medicina Tropical (SBMT)
Subjects:
Brazil
Cost-effectiveness analysis
Hepatitis C
Short Communication
Treatment
TROPICAL MEDICINE
Brazil
Cost-effectiveness analysis
Treatment
Hepatitis C
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:INTRODUCTIONWe conducted a cost-utility analysis of available interferon-free treatments for patients with early-stage genotype 1 chronic hepatitis C based on a Brazilian public health system perspective. METHODSA Markov model was derived using a cohort of stage F0-F2 patients treated as recommended by the Brazilian national guidelines. RESULTSGlecaprevir plus pibrentasvir was superior to all other treatments, followed by sofosbuvir plus velpatasvir. Sofosbuvir plus daclatasvir was identified as the least cost-effective option. CONCLUSIONSThe above findings were confirmed via probabilistic sensitivity analysis and the tested scenarios.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Authors’ contribution: VLF: designed the study, conducted all analysis, wrote the first draft of the manuscript and approved the final version of the manuscript; LPL: designed the study, analyzed the data, wrote the first draft of the manuscript and approved the final version of the manuscript; MLAP and RP: conceptualized and designed the study, supervised the project and approved the final version of the manuscript.
Conflict of Interest: The authors declare that there is no conflict of interest.
ISSN:0037-8682
1678-9849
1678-9849
DOI:10.1590/0037-8682-0594-2019